ADVENTRX Pharmaceuticals is a development-stage speciality pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of cancer. The Company seeks to improve the performance of existing drugs by addressing limitations associated principally with their safety and use.

ADVENTRX currently is focused on developing and seeking regulatory approval for two late-stage product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection), both of which are novel emulsion formulations of currently marketed chemotherapy drugs, and identifying and evaluating opportunities to expand our product pipeline.